MAOB and Parkinson disease: Consistent with the absence of or low interaction with MAO-B in our studies, a retrospective analysis, Hansen et al. [19] found that MAO-B inhibitors at therapeutic concentrations did not significantly affect [18F]flortaucipir binding in patients with Parkinson’s disease, in which MAO-B inhibitors are used to treat the disease.